WASHINGTON, September 29, 2005 (LifeSiteNews.com) – The newly appointed head of the US Food and Drug Administration is no friend to women, says Karen Malec, president of the Coalition on Abortion/Breast Cancer.
Andrew Von Eschenbach was named acting commissioner of the U.S. Food and Drug Administration (FDA) last Friday, following the abrupt and unexpected resignation of Commissioner Lester Crawford after just two months in the position. “Von Eschenbach is no friend of women,” warned Malec, a cancer survivor. “He’s a friend of the anti-woman abortion and pharmaceutical industries.”
Dr. Andrew Von Eschenbach was director of the U.S. National Cancer Institute (NCI), and as such was the head of an organization that has worked hard to cover up the connection between abortion and breast cancer. Malec warns, “Von Eschenbach can be relied upon to put in the ‘political fix’ for business interests.”
On August 26, Crawford announced that the decision on whether Plan B a post-coital abortifacient hormone treatment, would be distributed without a doctor’s prescription would be indefinitely delayed pending further investigation about its safety and proper use.
The delay prompted the feminist pro-abortifacient political activist, Susan Wood, then Assistant Commissioner for Women’s Health and Director, Office of Women’s Health, to resign in protest.
Pro-life groups and physicians associations have long warned that, apart from the abortifacient nature of so-called Morning After Pills like Plan B, the widespread use of MAP without doctor’s supervision, would lead to increases in sexually transmitted diseases like Human Papilloma Virus with an increase in the rate of cervical cancer associated with HPV.
Crawford’s resignation had prompted media speculation that his reasons were pressure from pharmaceutical interests and abortion lobbyists pushing to have MAP widely distributed. MAP is a cornerstone of the work of population control organizations who have been lobbying internationally for years for its broad distribution around the world. The training programme for pharmacists to teach them how to distribute the drug was funded by a who’s who of international population control groups.
Read related LifeSiteNews.com coverage:
FDA Delays Decision on Abortifacient Morning-After Pill Approval
https://www.lifesitenews.com/ldn/2005/aug/05082905.html
Women Now Safer that Activist has Resigned from FDA, Says Women’s Group
https://www.lifesitenews.com/ldn/2005/sep/05090103.html
hw